New Diabetes Drugs and Warfarin
By: Alere Staff
Diabetes remains a growing health epidemic in the United States with nearly one in every ten Americans being diagnosed. The American Diabetes Association found 9.3% of the population in 2012 had diabetes and, in 2010, it was labeled the seventh leading cause of death.1
Two new medications to treat diabetes were approved by the FDA in late 2013 and early 2014. A total of 25 separate studies were conducted to demonstrate safety and effectiveness of these two drugs that work differently than traditional medications. Traditional diabetic drugs target the liver, pancreas or intestine to improve the body’s management of sugar. These new drugs, canagliflozin and dapagliflozin, are in a new class of drugs called SGLT2 inhibitors. The drugs work by blocking the kidney’s reabsorption of glucose or sugar.2
Neither of the two oral medications reports any interactions with warfarin (or brand of warfarin such as Coumadin®) in their package insert. Patients are always advised however to report when they start or stop taking a medication to the clinician who manages their warfarin as additional blood tests may be needed and to the clinician beginning the diabetic treatment.
1. Website: http://www.diabetes.org/diabetes-basics/statistics/, retrieved July 21, 2014.
2. Website: http://health.clevelandclinic.org/2014/01/new-drug-makes-diabetics-pee-out-excess-sugar/, retrieved July 21, 2014.
COUMADIN® is a registered trademark of Bristol-Myers Squibb Pharma Company. Alere is not affiliated or associated with Bristol-Myers Squibb Pharma Company or the COUMADIN® trademark.